RESUMEN
DNA polymorphism is an important component of the interindividual variation in reactions of patients to the same drugs. In this work, evaluation of the association between polymorphisms in 106 genes involved in key processes of cellular activity (xenobiotic metabolism, DNA repair, the cell cycle, and apoptosis), and outcomes in a cohort of Yakut ovarian cancer patients receiving cisplatin-based chemotherapy was carried out. The polymorphism in the CDKN1B gene (rs34330) was found to be associated with complete tumor response and progression-free survival. SNPs in EPXH1 gene (rs2234922 and rs2260863) were correlated with hearing impairment. A SNP in NBN gene (rs1063045) was associated with severe emesis.
Asunto(s)
Cisplatino/administración & dosificación , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/genética , Estudios de Asociación Genética , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/genética , Apoptosis/genética , Ciclo Celular/genética , Reparación del ADN/genética , Supervivencia sin Enfermedad , Femenino , Predisposición Genética a la Enfermedad , Humanos , Estadificación de Neoplasias , Neoplasias Ováricas/patología , Farmacogenética , Polimorfismo de Nucleótido Simple , Federación de Rusia , Xenobióticos/metabolismoRESUMEN
The CYP2E1 gene polymorphism has been studied in Yakut women with ovarian cancer and without cancer. The two groups have been found to substantially differ in the frequency of the CYP2E1* 1D allele (with a 96-bp insertion in the promoter region of the gene): it is more frequent in healthy women (16.3 versus 7.4%, P = 0.007).